Role of membrane microdomains in PTH-mediated down-regulation of NaPi-IIa in opossum kidney cells

Kidney Int. 2005 Sep;68(3):1137-47. doi: 10.1111/j.1523-1755.2005.00505.x.

Abstract

Background: Parathyroid hormone (PTH) rapidly down-regulates type IIa sodium-dependent phosphate transporter (NaPi-IIa) via an endocytic pathway. Since the relationship between PTH signaling and NaPi-IIa endocytosis has not been explored, we investigated the role of membrane microdomains in this process.

Methods: We examined the submembrane localization of NaPi-IIa in opossum kidney (OK-N2) cells that stably expressed human NaPi-IIa, and searched for a PTH-induced specific phosphorylating substrate on their membrane microdomains by immunoblotting with specific antibody against phospho substrates of protein kinases.

Results: We found that NaPi-IIa was primarily localized in low-density membrane (LDM) domains of the plasma membrane; PTH reduced the levels of immunoreactive NaPi-IIa in these domains. Furthermore, PTH activated both protein kinase A (PKA) and protein kinase Calpha (PKCa) and increased the phosphorylation of 250 kD and 80 kD substrates; this latter substrate was identified as ezrin, which a member of the ezrin-radixin-moesin (ERM) protein family. In response to PTH, ezrin was phosphorylated by both PKA and PKC. Dominant negative ezrin blocked the reduction in NaPi-IIa expression in the LDM domains that was induced by PTH.

Conclusion: These data suggest that NaPi-IIa and PTH-induced phosphorylated proteins that include ezrin are compartmentalized in LDM microdomains. This compartmentalization may play an important role in the down-regulation of NaPi-IIa via endocytosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Cell Compartmentation / physiology*
  • Cell Line
  • Chlorpromazine / pharmacology
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Cyclodextrins / pharmacology
  • Cytochalasin D / pharmacology
  • Cytoskeletal Proteins
  • Dopamine Antagonists / pharmacology
  • Down-Regulation / drug effects
  • Endocytosis / physiology*
  • Humans
  • Immunohistochemistry
  • Kidney / cytology*
  • Nocodazole / pharmacology
  • Nucleic Acid Synthesis Inhibitors / pharmacology
  • Opossums
  • Parathyroid Hormone / pharmacology*
  • Phosphates / metabolism
  • Phosphoproteins / genetics
  • Phosphoproteins / metabolism
  • Phosphorylation / drug effects
  • Protein Kinase C-alpha / metabolism
  • Protein Structure, Tertiary
  • Sodium-Phosphate Cotransporter Proteins, Type IIa / chemistry
  • Sodium-Phosphate Cotransporter Proteins, Type IIa / genetics
  • Sodium-Phosphate Cotransporter Proteins, Type IIa / metabolism*

Substances

  • Antineoplastic Agents
  • Cyclodextrins
  • Cytoskeletal Proteins
  • Dopamine Antagonists
  • Nucleic Acid Synthesis Inhibitors
  • Parathyroid Hormone
  • Phosphates
  • Phosphoproteins
  • SLC34A1 protein, human
  • Sodium-Phosphate Cotransporter Proteins, Type IIa
  • ezrin
  • Cytochalasin D
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C-alpha
  • Nocodazole
  • Chlorpromazine